Malignant Tumor Clinical Trials

64 recruitingLast updated: June 18, 2026

There are 64 actively recruiting malignant tumor clinical trials across 15 countries. Studies span Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4. Top locations include Shanghai, Shanghai Municipality, China, Chengdu, Sichuan, China, Guangzhou, Guangdong, China. Updated daily from ClinicalTrials.gov.


Malignant Tumor Trials at a Glance

64 actively recruiting trials for malignant tumor are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 1 with 32 trials, with the heaviest enrollment activity in Shanghai, Chengdu, and Guangzhou. Lead sponsors running malignant tumor studies include Shenyang Sunshine Pharmaceutical Co., LTD., LaNova Medicines Limited, and Akeso.

Browse malignant tumor trials by phase

Treatments under study

About Malignant Tumor Clinical Trials

Looking for clinical trials for Malignant Tumor? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Malignant Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Malignant Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 64 trials

Recruiting
Not Applicable

Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors

Malignant Tumor
Alpha Tau Medical LTD.100 enrolled1 locationNCT05781555
Recruiting
Phase 1

Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors

Malignant Tumor
West China Hospital54 enrolled2 locationsNCT07567222
Recruiting
Phase 1

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Advanced Malignant Tumors
Bristol-Myers Squibb437 enrolled8 locationsNCT06764771
Recruiting

Correlation Analysis of Gene Characteristics of Malignant Tumors With Prognosis

Malignant Tumors
Nanfang Hospital, Southern Medical University500 enrolled1 locationNCT07622667
Recruiting
Not Applicable

High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

Pancreatic CancerMelanomaLiver Malignant Tumors+1 more
M.D. Anderson Cancer Center60 enrolled1 locationNCT05053555
Recruiting
Phase 1

A Clinical Study of SHR-4506 Injection in Patients With Malignant Tumors

Malignant Tumors of Adults
Suzhou Suncadia Biopharmaceuticals Co., Ltd.102 enrolled2 locationsNCT07068932
Recruiting

First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2

Malignant Tumor
First Hospital of China Medical University30 enrolled1 locationNCT07593209
Recruiting
Not Applicable

High-Resolution PET-CT Imaging for Surgical Margin Visualization

CancerHNSCCSCC - Squamous Cell Carcinoma+2 more
Vanderbilt-Ingram Cancer Center50 enrolled1 locationNCT06915454
Recruiting
Phase 2

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Hepatocellular CarcinomaMelanomaEsophageal Adenocarcinoma+5 more
Dan Zandberg72 enrolled1 locationNCT04114136
Recruiting
Not Applicable

Clinical Effectiveness of Microwave Ablation Using Starwave Microwave Generator for Hepatic Malignancies

Liver Malignant Tumors
Seoul National University Hospital128 enrolled1 locationNCT06426992
Recruiting
Phase 2

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

Breast CancerBreast CarcinomaBreast Neoplasm+34 more
University of California, Davis86 enrolled1 locationNCT06268665
Recruiting
Phase 1Phase 2

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Colorectal, CancerEsophageal CancerGastric Cancer+18 more
Neonc Technologies, Inc.134 enrolled6 locationsNCT06047379
Recruiting
Phase 1

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

NeoplasmCancer, Malignant Tumors
Compugen Ltd200 enrolled11 locationsNCT06759649
Recruiting
Not Applicable

Histotripsy for Ablation of Liver Tumours in Asia

Liver Malignant Tumors
National Cancer Centre, Singapore40 enrolled3 locationsNCT07428356
Recruiting
Not Applicable

Rehabilitation Outcomes Study

CancerMalignant Tumor
UNC Lineberger Comprehensive Cancer Center60 enrolled1 locationNCT06674889
Recruiting
Phase 1

A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors

Advanced Malignant Tumors
Shenyang Sunshine Pharmaceutical Co., LTD.96 enrolled1 locationNCT07038005
Recruiting
Phase 1Phase 2

Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease

Malignant TumorHyperthyroidism, AutoimmuneCardiovascular Abnormalities
Peking Union Medical College Hospital600 enrolled1 locationNCT07400224
Recruiting
Phase 1Phase 2

Efficacy and Safety of MSLN CAR-T in Advanced Malignant Tumors

Advanced Solid Malignant Tumors (With Positive Expression of MSLN in Tumor Tissue)
Shenzhen University General Hospital20 enrolled1 locationNCT07399769
Recruiting
Phase 1Phase 2

Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection

Biliary Malignant Tumors
Yifan Wang20 enrolled1 locationNCT07368803
Recruiting
Phase 1Phase 2

First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors

Advanced Malignant Tumors
Shanghai JMT-Bio Inc.436 enrolled1 locationNCT06877650